Thailand's Economy is Projected to Grow by 3% in 2024 with Government Stimulus Measures 
Tesla’s FSD Under NHTSA Probe Over Deadly Crashes Involving Sun Glare and Fog Risks 
ECB Rate Cuts Spark Traders' Optimism Amid Economic Uncertainty 
Gold Prices Soar Amid U.S. Election Uncertainty and ECB Rate Cut 
Italy Drops Bitcoin Tax Bombshell: Capital Gains to Soar to 42% in Shocking Budget Move 
Hyundai Motor India Sets IPO Price at ₹1,960, Targeting $3.3 Billion 
Meta Fires Employees for Buying Toothpaste! ‘Forget Lunch, These Perks Have Gone Too Far,’ Company Insiders Reveal 
Tesla Launches First Superchargers in Chile, Expanding EV Infrastructure Across South America 
AB Volvo Reports Larger-than-Expected Drop in Q3 Profit Amid Normalizing Truck Demand 
China Central Bank Launches 800 Billion Yuan Funding to Boost Stock Market Stability 
Samsung's AI Move Could Eliminate Settings Menu Forever—Say Goodbye to Manual Adjustments 
Tesla Launches Wireless Charging: Cybertruck and Robotaxi Shed the Plug 
Shiba Inu Volume Soars 21% to $206M – Is a Massive SHIB Price Rally Coming? 
U.S. Commerce Department Investigates TSMC for Potential Export Violations 
Shiba Inu Whales Abandon Trillionaire Status: SHIB Faces Uncertain Waters 
Apple’s Secret Alliance With BYD: Years-Long EV Battery Development Exposed 
Samsung Biologics revealed on Monday, Sept. 18, that it has closed a contract manufacturing organization deal (CMO) with Bristol-Myers Squibb to produce immunotherapy medications until 2030. The contract is said to be worth $242 million.
Bristol-Myers Squibb is one of the long-term customers of Samsung Biologics, so this is just another deal for a new production request. They have been working together for the CMO business since 2013. In any case, on the part of the Korean biopharmaceutical company, this contract has been added to its streak of wins for CMO projects this year alone.
Collectively, the company is close to hitting the KRW3 trillion or $2.26 billion mark for all of its deals so far in 2023. Reaching this amount is said to be a milestone for Samsung Biologics as it is happening for the first time.
As per The Korea Herald, as of September 2023, the Incheon-based biotechnology firm was able to secure contract manufacturing deals with 14 of the world’s top 20 pharmaceuticals. Novartis and Pfizer are the other major brands that signed large-scale agreements with the company.
Meanwhile, Samsung Biologics agreed to produce immunotherapies of Bristol-Myers Squibb. These will be manufactured in its fourth plant in the span of seven years.
An official of the biotech arm of the Samsung Group said, “Securing the latest deal was possible as Samsung Biologics has proved itself as a reliable contract manufacturer to its global partners, with its large production capacity, fast manufacturing speeds and consistent, high-quality output.”
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” Samsung Biologics’ president and chief executive officer, John Rim, further said in a statement. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
Photo by: Samsung Biologics Newsroom
